

IDS - 06/12/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| | |
|------------------------|------------------|
| Application Number | 10567801 |
| Filing Date | 2006-02-09 |
| First Named Inventor | Bennett |
| Art Unit | |
| Examiner Name | Not yet assigned |
| Attorney Docket Number | 101181-1P US |

| U.S. PATENTS | | | | | | Remove |
|-------------------|---------|---------------|------------------------|------------|---|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
| SY | 1 | 3706810 | | 1972-12-19 | American Cyanamid Company | |
| SY | 2 | 4599198 | | 1986-07-08 | Pfizer Inc. | |
| SY | 3 | 4668769 | | 1987-05-26 | Dennis J. Hoover | |
| SY | 4 | 4692522 | | 1987-09-08 | Merck & Co., Inc. | |
| SY | 5 | 4720503 | | 1988-01-19 | Merck & Co., Inc. | |
| SY | 6 | 4751231 | | 1988-06-14 | Merck & Co., Inc. | |
| SY | 7 | 4786641 | | 1988-11-22 | Bayer Aktiengesellschaft | |
| SY | 8 | 4794120 | | 1988-12-27 | Synthelabo | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|----------------------------|
| Application Number | 10567801 |
| Filing Date | 2006-02-09 |
| First Named Inventor | Stuart Norman Lile Bennett |
| Art Unit | 1626 |
| Examiner Name | Young, Shawquia |
| Attorney Docket Number | 101181-1P US |

| | | | |
|------|---|---|--------------------------|
| /SY/ | 1 | S. FREEMAN et al, Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme, British Journal of Pharmacology, 2006, 775-785, 149 | <input type="checkbox"/> |
|------|---|---|--------------------------|

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Shawquia Young/ | Date Considered | 03/26/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------|------------|
| Application Number | | 10567801 |
| Filing Date | | 2006-02-09 |
| First Named Inventor | Bennett | |
| Art Unit | | |
| Examiner Name | Not yet assigned | |
| Attorney Docket Number | 101181-1P US | |

| | | | | | | |
|----|----|---------|--|------------|------------------|--|
| SY | 9 | 5863903 | | 1999-01-26 | Novo Nordisk A/S | |
| SY | 10 | 5998463 | | 1999-12-07 | Pfizer Inc. | |

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS

Remove

| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|--------------------|------------------------|------------------|---|--|
| | 1 | | | | | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
|-------------------|---------|--------------------------------------|---------------------------|------------------------|------------------|---|--|-------------------------------------|
| SY | 1 | 200740 | DD | A | 1983-06-08 | Karl Gewald et. al. | | <input checked="" type="checkbox"/> |
| SY | 2 | 4445968 | DE | A1 | 1996-06-27 | Bayer AG | | <input checked="" type="checkbox"/> |
| SY | 3 | 0697403 | EP | A1 | 1996-02-21 | Sanofi | | <input checked="" type="checkbox"/> |
| SY | 4 | 0846464 | EP | A2 | 1998-06-10 | Pfizer Inc | | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------|------------|
| Application Number | | 10567801 |
| Filing Date | | 2006-02-09 |
| First Named Inventor | Bennett | |
| Art Unit | | |
| Examiner Name | Not yet assigned | |
| Attorney Docket Number | 101181-1P US | |

| | | | | | | | | |
|----|----|---------|----|----|------------|-----------------------------------|--|-------------------------------------|
| SY | 5 | 0884050 | EP | A1 | 1998-12-16 | Novo Nordisk A/S | | <input type="checkbox"/> |
| SY | 6 | 0978279 | EP | A1 | 2000-02-09 | Pfizer Products Inc. | | <input type="checkbox"/> |
| SY | 7 | 1088824 | EP | A2 | 2001-04-04 | Pfizer Products Inc. | | <input type="checkbox"/> |
| SY | 8 | 1125580 | EP | A2 | 2001-08-22 | Pfizer Products Inc. | | <input type="checkbox"/> |
| SY | 9 | 1134213 | EP | A2 | 2001-09-19 | Pfizer Inc. | | <input type="checkbox"/> |
| SY | 10 | 1136071 | EP | A2 | 2001-09-26 | Pfizer Products Inc. | | <input type="checkbox"/> |
| SY | 11 | 1145717 | EP | A2 | 2001-10-17 | Pfizer Products Inc. | | <input type="checkbox"/> |
| SY | 12 | 1149580 | EP | A1 | 2001-10-31 | Pfizer Products Inc. | | <input type="checkbox"/> |
| SY | 13 | 1177791 | EP | A2 | 2002-02-06 | Pfizer Products Inc. | | <input type="checkbox"/> |
| SY | 14 | 1340500 | EP | A1 | 2003-09-03 | Pfizer Products Inc | | <input type="checkbox"/> |
| SY | 15 | 2081747 | ES | A1 | 1996-03-01 | Laboratories del Dr. Esteve, S.A. | | <input checked="" type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------|------------|
| Application Number | | 10567801 |
| Filing Date | | 2006-02-09 |
| First Named Inventor | Bennett | |
| Art Unit | | |
| Examiner Name | Not yet assigned | |
| Attorney Docket Number | 101181-1P US | |

| | | | | | | | |
|----|----|-------------|----|----|------------|--|-------------------------------------|
| SY | 16 | 04179949 | JP | A | 1992-06-26 | Fuji Photo Film CO., Ltd. | <input checked="" type="checkbox"/> |
| SY | 17 | 2001 089368 | JP | A | 2001-04-03 | Tanabe Seiyaku Co., Ltd | <input checked="" type="checkbox"/> |
| SY | 18 | 2001 206856 | JP | A | 2001-07-31 | Pfizer Products Inc. | <input checked="" type="checkbox"/> |
| SY | 19 | 2001 247565 | JP | A | 2001-09-11 | Pfizer Products Inc | <input checked="" type="checkbox"/> |
| SY | 20 | 2004 196702 | JP | A | 2004-07-15 | Yamanouchi Pharmaceuticals Co., Ltd. | <input checked="" type="checkbox"/> |
| SY | 21 | 93/25574 | WO | A1 | 1993-12-23 | Pfizer Inc. | <input type="checkbox"/> |
| SY | 22 | 95/24391 | WO | A1 | 1995-09-14 | Novo Nordisk A/S | <input type="checkbox"/> |
| SY | 23 | 96/39384 | WO | A1 | 1996-12-12 | Pfizer Inc. | <input type="checkbox"/> |
| SY | 24 | 96/39385 | WO | A1 | 1996-12-12 | Pfizer Inc. | <input type="checkbox"/> |
| SY | 25 | 97/09040 | WO | A1 | 1997-03-13 | Novo Nordisk | <input type="checkbox"/> |
| SY | 26 | 97/31901 | WO | A1 | 1997-09-04 | Mikael Bols | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------|------------|
| Application Number | | 10567801 |
| Filing Date | | 2006-02-09 |
| First Named Inventor | Bennett | |
| Art Unit | | |
| Examiner Name | Not yet assigned | |
| Attorney Docket Number | 101181-1P US | |

| | | | | | | | | |
|----|----|----------|----|----|------------|---|--|--------------------------|
| SY | 27 | 97/45425 | WO | A1 | 1997-12-04 | Fujisawa Pharmaceutical Co., Ltd. | | <input type="checkbox"/> |
| SY | 28 | 98/27108 | WO | A2 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | | <input type="checkbox"/> |
| SY | 29 | 98/40353 | WO | A1 | 1998-09-17 | Novo Nordisk A/S | | <input type="checkbox"/> |
| SY | 30 | 98/50359 | WO | A1 | 1998-11-12 | Novo Nordisk A/S | | <input type="checkbox"/> |
| SY | 31 | 99/26659 | WO | A1 | 1999-06-03 | Pfizer Products Inc. | | <input type="checkbox"/> |
| SY | 32 | 99/36393 | WO | A1 | 1999-07-22 | Tanabe Seiyaku Co., Ltd. | | <input type="checkbox"/> |
| SY | 33 | 00/42213 | WO | A1 | 2000-07-20 | The Research Foundation of State University of NY | | <input type="checkbox"/> |
| SY | 34 | 00/47206 | WO | A1 | 2000-08-17 | Novo Nordisk A/S | | <input type="checkbox"/> |
| SY | 35 | 01/05954 | WO | A1 | 2001-01-25 | Isis Pharmaceuticals Inc | | <input type="checkbox"/> |
| SY | 36 | 01/23347 | WO | A1 | 2001-04-05 | Novo Nordisk A/S | | <input type="checkbox"/> |
| SY | 37 | 01/32622 | WO | A1 | 2001-05-10 | AstraZeneca AB | | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------|------------|
| Application Number | | 10567801 |
| Filing Date | | 2006-02-09 |
| First Named Inventor | Bennett | |
| Art Unit | | |
| Examiner Name | Not yet assigned | |
| Attorney Docket Number | 101181-1P US | |

| | | | | | | | |
|----|----|----------|----|----|------------|---|-------------------------------------|
| SY | 38 | 01/32654 | WO | A2 | 2001-05-10 | Societe de Conseils de Recherches et D'App Sci | <input checked="" type="checkbox"/> |
| SY | 39 | 01/52825 | WO | A2 | 2001-07-26 | Novartis AG | <input type="checkbox"/> |
| SY | 40 | 01/68055 | WO | A1 | 2001-09-20 | Pfizer Products Inc. | <input type="checkbox"/> |
| SY | 41 | 01/68092 | WO | A2 | 2001-09-20 | Pfizer Products Inc. | <input type="checkbox"/> |
| SY | 42 | 01/68603 | WO | A2 | 2001-09-20 | Bristol-Myers Squibb Co. | <input type="checkbox"/> |
| SY | 43 | 01/94300 | WO | A1 | 2001-12-13 | Aventis Pharma Deutschland GMBH | <input checked="" type="checkbox"/> |
| SY | 44 | 01/96311 | WO | A2 | 2001-12-20 | Bristol-Myers Squibb Company | <input type="checkbox"/> |
| SY | 45 | 01/96347 | WO | A1 | 2001-12-20 | Bristol-Myers Squibb Company | <input type="checkbox"/> |
| SY | 46 | 02/20530 | WO | A1 | 2002-03-14 | AstraZeneca AB | <input type="checkbox"/> |
| SY | 47 | 02/26714 | WO | A1 | 2002-04-04 | Takeda Chemical Industries | <input checked="" type="checkbox"/> |
| SY | 48 | 02/34718 | WO | A1 | 2002-05-02 | Richter Gedeon Vegyeszeti Gyar RT | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------|------------|
| Application Number | | 10567801 |
| Filing Date | | 2006-02-09 |
| First Named Inventor | Bennett | |
| Art Unit | | |
| Examiner Name | Not yet assigned | |
| Attorney Docket Number | 101181-1P US | |

| | | | | | | | |
|----|----|----------|----|----|------------|----------------------|-------------------------------------|
| SY | 49 | 02/36583 | WO | A1 | 2002-05-10 | Shionogi & Co., Ltd. | <input checked="" type="checkbox"/> |
| SY | 50 | 02/80844 | WO | A2 | 2002-10-17 | Genzyme Corporation | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T5 |
|--------------------|---------|---|--------------------------|
| SY | 1 | CROCHET R.A., et al., J. Het. Chem., "Synthesis of Substituted Thieno[2,3-b] pyrroles," April 1974, 143-150, Vol. 11. | <input type="checkbox"/> |
| SY | 2 | HARTMAN G.D., et al., "The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides," Heterocycles, 1989, 1943-1949, Vol. 29(10). | <input type="checkbox"/> |
| SY | 3 | MCCORMACK J.G., et al., "Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy," Curr. Pharmaceutical Design, 2001, 1451-1474, Vol. 7. | <input type="checkbox"/> |
| SY | 4 | JAKOBSEN P., et al., "Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase.," Bioorganic Med. Chem., 2001, 733-744, Vol. 9. | <input type="checkbox"/> |
| SY | 5 | TREADWAY J.L., et al., "Glycogen phosphorlase inhibitors for treatment of type 2 diabetes mellitus," Exp. Opin. Invest. Drugs, 2001, 439-454, Vol. 10(3). | <input type="checkbox"/> |
| SY | 6 | RATH V.L. et al., "Activation of Human Liver Glycogen Phosphorylase by Alteration of the Secondary Structure and Packing of the Catalytic Core," Mol. Cell, July 2000, 139-148, Vol. 6. | <input type="checkbox"/> |
| SY | 7 | OIKONOMAKOS N.G., et al., "Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate," Protein Sci., 1999, 1930-1945, Vol. 8. | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------|--------------|
| Application Number | | 10567801 |
| Filing Date | | 2006-02-09 |
| First Named Inventor | Bennett | |
| Art Unit | | |
| Examiner Name | Not yet assigned | |
| Attorney Docket Number | | 101181-1P US |

| | | | |
|----|----|---|--------------------------|
| SY | 8 | VENKATARANGAN P., et al., "Prediction of Ligand-Receptor Binding Thermodynamics by Free Energy Force Field Three-Dimensional Quantitative Structure-Activity Relationship Analysis: Applications to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase," J. Med. Chem., 1999, 2169-2179, Vol. 42. | <input type="checkbox"/> |
| SY | 9 | HOOVER D.J., et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase," J. Med. Chem., 1998, 2934-2938, Vol. 41. | <input type="checkbox"/> |
| SY | 10 | MARTIN W.H., et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo," PNAS, Feb. 1998, 1776-1781, Vol. 95. | <input type="checkbox"/> |
| SY | 11 | SOMAN G., et al., "The Nature of the Binding Site for Aromatic Compounds in Glycogen Phosphorylase b," Biochem. J., 1975, 369-371, Vol. 147. | <input type="checkbox"/> |
| SY | 12 | SOMAN G., et al. "Aromatic Compounds as Allosteric Inhibitors of Glycogen Phosphorylase b," Biochimica et Biophysica Acta, 1974, 359-362, Vol. 358. | <input type="checkbox"/> |
| SY | 13 | ROSAUER K.G., et al., "Novel 3,4-Dihydroquinolin-2(1H)-one Inhibitors of Human Glycogen Phosphorylase a," Bioorganic & Medicinal Chemistry Letters, 2003, 4385-4388, Vol. 13. | <input type="checkbox"/> |
| SY | 14 | TEAGUE J. et al., "Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat," Diabetes, 53, Supp. 2, 2004, A365, 1521-P. | <input type="checkbox"/> |
| SY | 15 | VERTIGAN H. et al., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents," Diabetologia, 2004, A214, 589, Vol. 47, Supp.1. | <input type="checkbox"/> |
| SY | 16 | FONT M. et al. "Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase", European Journal Med Chem, 1995, 963-71, Vol. 30. | <input type="checkbox"/> |
| SY | 17 | LIN T. et al. "Effects of Protein Binding and Experimental Disease States on Brain Uptake of Benzodiazepines in Rats", J Pharmacology & Eptl Therapeutics, 1990, 45-50, Vol. 253(1). | <input type="checkbox"/> |
| SY | 18 | VARNAVAS A. et al. "Quinolone Derivatives: Synthesis and Binding Evaluation on Cholecystokinin Receptors", Il Farmaco, 1996, 341-350, Vol. 51(5). | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------|------------|
| Application Number | | 10567801 |
| Filing Date | | 2006-02-09 |
| First Named Inventor | Bennett | |
| Art Unit | | |
| Examiner Name | Not yet assigned | |
| Attorney Docket Number | 101181-1P US | |

| | | | |
|----|----|---|--------------------------|
| SY | 19 | PARSONS W H. et al. "Cholecystokinin Antagonists. Synthesis and Biological Evaluation of 3-Substitued Benzolactams", J Med Chem, 1989, 1681-5, Vol. 32. | <input type="checkbox"/> |
| SY | 20 | FREEMAN S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor," Diabetes, 52, Supp., 2003, A340, 1470-P. | <input type="checkbox"/> |
| SY | 21 | TURNBULL A., et al., "Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes," Diabetes, 52, Supp., 2003, A343, 1485-P. | <input type="checkbox"/> |
| SY | 22 | BIRCH A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, Cambridge Med Chem Symposium, Sept 2003. | <input type="checkbox"/> |
| SY | 23 | HUDSON S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 2002, 52-53, Vol. 539. | <input type="checkbox"/> |
| SY | 24 | VERTIGAN H. et al., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents", EASD Munich, 2004. | <input type="checkbox"/> |
| SY | 25 | BARTLETT J. et al., "In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase", ADA San Diego, 2005. | <input type="checkbox"/> |
| SY | 26 | BENNETT S N L. et al., "Novel Orally Active Amino-indan Inhibitors of Glycogen Phosphorylase", Cambridge Med Chem Conference, Sept 2005. Poster EOM. | <input type="checkbox"/> |
| SY | 27 | GREEN A R. et al., "The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation", J Biol Chem, 2004, 46474-46482, Vol. 279(45). | <input type="checkbox"/> |
| SY | 28 | ROBERTS P A. et al., "The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle", J Physiology, 2002, 297-304, Vol. 545(1). | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|------------------|
| Application Number | 10567801 |
| Filing Date | 2006-02-09 |
| First Named Inventor | Bennett |
| Art Unit | |
| Examiner Name | Not yet assigned |
| Attorney Docket Number | 101181-1P US |

EXAMINER SIGNATURE

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Shawquia Young/ | Date Considered | 01/08/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

IDS - 06/12/2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| | |
|------------------------|------------------|
| Application Number | 10567801 |
| Filing Date | 2006-02-09 |
| First Named Inventor | Bennett |
| Art Unit | |
| Examiner Name | Not yet assigned |
| Attorney Docket Number | 101181-1P US |

| U.S.PATENTS | | | | | | Remove |
|-------------------|---------|---------------|------------------------|------------|---|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

| U.S.PATENT APPLICATION PUBLICATIONS | | | | | | Remove |
|-------------------------------------|---------|--------------------|------------------------|------------------|---|--|
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
| SY | 1 | 20040002495 | A1 | 2004-01-01 | Philip Sher et. al. | |
| SY | 2 | 20040082641 | A1 | 2004-04-29 | Klaus Asger Rytved et. al. | |
| SY | 3 | 20040142938 | A1 | 2004-07-22 | Philip M. Sher et. al. | |
| SY | 4 | 20040220229 | A1 | 2004-11-04 | Donald L. Bussolotti et. al. | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

| FOREIGN PATENT DOCUMENTS | | | | | | | | Remove |
|--------------------------|---------|--------------------------------------|---------------------------|------------------------|------------------|---|--|----------------|
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------|------------|
| Application Number | | 10567801 |
| Filing Date | | 2006-02-09 |
| First Named Inventor | Bennett | |
| Art Unit | | |
| Examiner Name | Not yet assigned | |
| Attorney Docket Number | 101181-1P US | |

| | | | | | | | |
|----|----|-----------|----|----|------------|------------------------------------|-------------------------------------|
| SY | 1 | 02/96864 | WO | A1 | 2002-12-05 | Aventis Pharma Deutschland GmbH | <input checked="" type="checkbox"/> |
| SY | 2 | 02/98348 | WO | A2 | 2002-12-12 | Eli Lilly and Company | <input type="checkbox"/> |
| SY | 3 | 03/037864 | WO | A1 | 2003-05-08 | Japan Tobacco Inc. | <input checked="" type="checkbox"/> |
| SY | 4 | 03/045920 | WO | A1 | 2003-06-05 | Merck & Co., Inc. | <input type="checkbox"/> |
| SY | 5 | 03/072570 | WO | A1 | 2003-09-04 | Pfizer Products Inc | <input type="checkbox"/> |
| SY | 6 | 03/074484 | WO | A1 | 2003-09-12 | AstraZeneca AB | <input type="checkbox"/> |
| SY | 7 | 03/074485 | WO | A2 | 2003-09-12 | AstraZeneca AB | <input type="checkbox"/> |
| SY | 8 | 03/074513 | WO | A2 | 2003-09-12 | AstraZeneca AB | <input type="checkbox"/> |
| SY | 9 | 03/074517 | WO | A1 | 2003-09-12 | AstraZeneca AB | <input type="checkbox"/> |
| SY | 10 | 03/074531 | WO | A1 | 2003-09-12 | AstraZeneca AB | <input type="checkbox"/> |
| SY | 11 | 03/074532 | WO | A1 | 2003-09-12 | AstraZeneca AB | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------|--------------|
| Application Number | | 10567801 |
| Filing Date | | 2006-02-09 |
| First Named Inventor | Bennett | |
| Art Unit | | |
| Examiner Name | Not yet assigned | |
| Attorney Docket Number | | 101181-1P US |

| | | | | | | | |
|----|----|-------------|----|----|------------|--|-------------------------------------|
| SY | 12 | 03/091213 | WO | A1 | 2003-11-06 | Yamanouchi Pharmaceutical Co., Ltd. | <input checked="" type="checkbox"/> |
| SY | 13 | 2004/031193 | WO | A1 | 2004-04-15 | AstraZeneca AB | <input type="checkbox"/> |
| SY | 14 | 2004/031194 | WO | A1 | 2004-04-15 | AstraZeneca AB | <input type="checkbox"/> |
| SY | 15 | 2004/041780 | WO | A2 | 2004-05-21 | Pfizer Products Inc. | <input type="checkbox"/> |
| SY | 16 | 2004/078743 | WO | A1 | 2004-09-16 | Aventis Pharma Deutschland GMBH | <input checked="" type="checkbox"/> |
| SY | 17 | 2004/092158 | WO | A1 | 2004-10-28 | Pfizer Products Inc | <input type="checkbox"/> |
| SY | 18 | 2004/104001 | WO | A2 | 2004-12-02 | OSI Pharmaceuticals, Inc. | <input type="checkbox"/> |
| SY | 19 | 2004/113345 | WO | A1 | 2004-12-29 | Japan Tobacco Inc. | <input checked="" type="checkbox"/> |
| SY | 20 | 2005/013975 | WO | A1 | 2005-02-17 | AstraZeneca AB | <input type="checkbox"/> |
| SY | 21 | 2005/013981 | WO | A1 | 2005-02-17 | AstraZeneca AB | <input type="checkbox"/> |
| SY | 22 | 2005/019172 | WO | A1 | 2005-03-03 | AstraZeneca AB | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | | |
|------------------------|------------------|--------------|--|
| Application Number | | 10567801 | |
| Filing Date | | 2006-02-09 | |
| First Named Inventor | Bennett | | |
| Art Unit | | | |
| Examiner Name | Not yet assigned | | |
| Attorney Docket Number | | 101181-1P US | |

| | | | | | | | | |
|----|----|-------------|----|----|------------|--------------------------------|--|--------------------------|
| SY | 23 | 2005/020985 | WO | A1 | 2005-03-10 | AstraZeneca AB | | <input type="checkbox"/> |
| SY | 24 | 2005/020986 | WO | A1 | 2005-03-10 | AstraZeneca AB | | <input type="checkbox"/> |
| SY | 25 | 2005/020987 | WO | A1 | 2005-03-10 | AstraZeneca AB | | <input type="checkbox"/> |
| SY | 26 | 2005/067932 | WO | A1 | 2005-07-28 | Janssen Pharmaceutica, N.V. | | <input type="checkbox"/> |
| SY | 27 | 2005/085194 | WO | A2 | 2005-09-15 | Prosidion Limited | | <input type="checkbox"/> |
| SY | 28 | 2005/085245 | WO | A1 | 2005-09-15 | Prosidion Limited | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|-----------------------|------------|---|--------------------------|
| | 1 | | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Shawquia Young/ | Date Considered | 01/08/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| | |
|------------------------|----------------------------|
| Application Number | 10567801 |
| Filing Date | 2006-02-09 |
| First Named Inventor | Stuart Norman Lile Bennett |
| Art Unit | 1626 |
| Examiner Name | Young, Shawquia |
| Attorney Docket Number | 101181-1P US |

U.S. PATENTS

[Remove](#)

| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|---------------|------------------------|------------|---|--|
| | 1 | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS

[Remove](#)

| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|--------------------|------------------------|------------------|---|--|
| | 1 | | | | | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
|-------------------|---------|--------------------------------------|---------------------------|------------------------|------------------|---|--|--------------------------|
| | 1 | | | | | | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button.

[Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|---------|---|----------------|
| | | | |